Posted on February 7, 2020 by Sitemaster
So your sitemaster has been looking through the full report from the APCCC meeting held in Basel last year — as he promised he would. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: advanced, castration-resistant, consensus, hormone-naive, hormone-sensitive, mCRPC, metastatic, mHSPC, nmCRPC, nmHSPC, non-metastatic | 2 Comments »
Posted on February 3, 2020 by Sitemaster
Last August your sitemaster attended and reported from the third iteration of the Advanced Prostate Cancer Consensus Conference (APCCC), held in Basel, Switzerland (see here, here, and here). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: advanced, APCCC, conference, consensus | Leave a comment »
Posted on February 3, 2020 by Sitemaster
According to a media release issued by Bayer a couple of days ago, the combination of androgen deprivation therapy (ADT) + darolutamide (Nubeqa) extends overall survival “significantly” in men with non-metastatic, castration-resistant prostate cancer (nmCRPC). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, darolutamide, nmCRPC, non-metastatic, overall, survival | 2 Comments »
Posted on December 21, 2019 by Sitemaster
Ideally, a new diagnostic and therapy (“theranostic”) will have the following qualities:
- It will be theranostic for all cancers (high sensitivity)
- It will not be theranostic of anything that isn’t cancer (high specificity)
… READ MORE …
Filed under: Drugs in development | Tagged: FAPI, fibroblast, fibroblast-activating, theranostic | Leave a comment »
Posted on December 19, 2019 by Sitemaster
Lu-177-PSMA usually improves survival
We’ve seen in a couple of small trials in Germany and Australia that Lu-177-PSMA seemed to provide better than expected survival. … READ MORE … -p>
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: Lu-177-PSMA, lutetium-177, metastatic, PSMA | 5 Comments »
Posted on December 17, 2019 by Sitemaster
Yesterday the U.S. Food and Drug Administration (FDA) approved the use of enzalutamide (Xtandi) for the treatment of metastatic, hormone-sensitive prostate cancer (mHSPC) — also known as metastatic, castration-rsensitive prostate cancer or mCSPC. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: enzalutamide, hormone-sensitive, HSPC, metastatic, Xtandi | 3 Comments »
Posted on October 1, 2019 by Sitemaster
From a report presented by Hussain yesterday at the annual meeting of the European Society for Medical Oncology (ESMO) we gained detailed insight into the results of the PROfound trial of olaparib (Lynparza), which had been said to be positive last August. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, gene, Lynparza, mCRPC, metastatic, mutation, olaparib | 3 Comments »
